Olema Pharma Q3 net loss widens on higher costs
OLMA•Olema Pharma's third-quarter net loss widened to $73.6 million as higher research, development and clinical trial costs increased expenses. The company ended the quarter with $413.8 million in cash and equivalents and expects top-line data from its Phase 3 OPERA-01 trial in Q1 2027.
1. Quarterly results
Olema Pharma reported a third-quarter net loss of $73.6 million and operating expenses of $77.53 million. Higher research and development, manufacturing and personnel costs contributed to increased expenses, along with higher general and administrative spending.
2. Trials and cash
The company ended the quarter with $413.8 million in cash and equivalents. It expects top-line data from its Phase 3 OPERA-01 trial in Q1 2027 and said enrollment continues in the Phase 3 OPERA-02 and Phase 1b/2 OP-3136 trials. Olema plans to start a Phase 1b/2 OP-3136 and darolutamide study in Q4 2026.
